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TObjectives: The C-Port System (Cardica, Inc, Redwood City, Calif) integrates in
one tool all functions necessary to enable rapid automated distal coronary anasto-
moses. The goal of this prospective, nonrandomized, and multicenter study is to
determine the safety and efficacy of this novel anastomotic system.
Methods: Five centers enrolled 133 patients awaiting elective coronary artery
bypass grafting surgery. Outcome variables were intraoperative device performance,
incidence of device-related adverse events, predischarge and 6-month angiographic
graft patency, and 12-month clinical outcome. Independent core laboratories performed
qualitative and quantitative angiographic and computed tomographic assessments.
Results: The C-Port was used to perform a vein-to-coronary anastomosis in 130
patients. Intraoperative conversion to a hand-sewn anastomosis was necessary in 11
patients because of inadequate target site preparation, inappropriate target vessel
selection, or both. Inadequate blood flow related to poor runoff required conversion
in 3 additional patients. Three patients died before discharge of causes unrelated to
the device. At discharge, 113 patients had a C-Port implant in place, and 104 C-Port
anastomoses were studied by means of angiography, resulting in 100 FitzGibbon A,
3 FitzGibbon B, and 1 FitzGibbon 0 classifications. At 6 months, one additional
patient died of a device-unrelated cause, and 98 patients were evaluated by means
of angiography (n  89). Overall patency (FitzGibbon A) was 92.1%. Three C-Port
anastomoses were rated FitzGibbon B, and 4 were rated FitzGibbon 0. At 12
months, 107 (98.2%) of 109 alive patients were followed up, without any reports of
device-related major adverse cardiac events.
Conclusions: The C-Port System allows for a rapid, reliable, and compliant distal
anastomosis and yields favorable 6-month angiographic and 12-month clinical
results when compared with published studies.
In coronary artery bypass grafting (CABG) hand-sewn anastomoses are consid-ered the gold standard. These are performed with either a running or aninterrupted suture technique.1 In the era of surgical intervention with conven-
tional sternotomy and an arrested heart, these suturing techniques yield excellent
results, despite being time-consuming, difficult to perform in a confined space, and
associated with a significant learning curve. The introduction of less invasive
surgical approaches and beating-heart surgery has triggered an interest in the
development of anastomotic devices. These devices are intended to enable rapid,
precise, and reliable anastomoses to further enhance minimally invasive coronary
bypass surgery.2
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ETRecently, the Cardica C-Port Anastomotic System (Cardica,
Inc, Redwood City, Calif) has been introduced to facilitate
saphenous venous graft–to–coronary artery anastomoses.
The C-Port System allows rapid automated distal coronary
anastomoses by integrating all the functions necessary for
completing an anastomosis. A compliant, angled, end-to-
side anastomosis is performed by automatically placing 8
individual clips and creating an arteriotomy with the push of
a button.
This multicenter clinical trial investigated the safety and
efficacy of the C-Port device in the construction of distal
coronary anastomoses.
Materials and Methods
After obtaining local ethics committee approval and informed
patient consent, this study was performed as a prospective, non-
randomized clinical trial in patients referred to the investigators for
multivessel CABG.
Study inclusion criteria were age greater than 18 years and less
than 85 years, ejection fraction of greater than 30%, creatinine
value of less than 200 mmol/L, and the requirement for nonemer-
gency bypass of at least one coronary artery. Exclusion criteria
were previous CABG surgery, the preoperative need for an intra-
aortic balloon counterpulsation, bleeding diathesis, a recent cere-
brovascular accident, and patients in New York Heart Association
(NYHA) class IV.
The study design included a perioperative assessment with
predischarge angiography, intermediate patency evaluation at 6
months, and longer-term (12-month) clinical follow-up with rest-
ing and stress electrocardiography (ECG) and assessment of major
adverse cardiac events (MACEs). A MACE was defined as the
presence of death, myocardial infarction, or the need for target
vessel revascularization.
Anastomotic System
The C-Port device (Figure 1) integrates in one tool all functions
necessary to enable rapid automated distal coronary anastomoses.
When using the Cardica C-Port System, a vein is harvested from
the patient’s leg by conventional means and is attached to the
cartridge of the C-Port deployment device (Figure 2). The surgeon
creates a small incision in the target vessel. The graft is then
inserted between the 2 cartridge arms and attached by 4 small
spikes. This system is suitable for coronary arteries as small as 1
mm in internal diameter. A small incision is created in the target
vessel, and the anvil of the C-Port is inserted. The connection
between the vein graft and the coronary artery can then be per-
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CT  computed tomography
ECG  electrocardiography
MACEmajor adverse cardiac event
NYHA New York Heart Associationformed rapidly, without the need for temporary occlusion of the
1646 The Journal of Thoracic and Cardiovascular Surgery ● Dectarget vessel. Deployment is accomplished by depressing a trigger
button on the deployment handle, which first approximates the
cartridge onto the coronary target and then deploys 8 individual
stainless-steel anastomotic clips that penetrate the graft and target
vessels and form against the anvil inside the coronary artery. Each
clip has 4 tines that form in pairs for a total of 32 points of tissue
approximation. A knife located within the anvil is deployed simul-
taneously and cuts the coronary artery from the inside out, thereby
creating the arteriotomy. The cartridge then unclamps, and the
device is removed from the anastomosis site through the previ-
ously created incision. A stitch is necessary in most instances to
occlude the anvil insertion hole, and additional stitches might be
necessary to provide hemostasis at the toe and heel (Figure 3).
In the present study clinically unsuccessful deployments were
observed and caused by the inability of the cartridge to align with
the anvil as a result of inadequate target site preparation. In these
situations the surgeon removes the deployment devices and is
confronted with an anvil insertion hole of approximately 1 mm and
no attachment of the graft to the coronary vessel but also no further
damage to the graft or target vessel. The surgeon must therefore
only extend the anvil insertion hole to the desired length necessary
for a hand-sewn anastomosis. In events in which the C-Port anas-
tomosis was technically successful but the surgeon decided to
convert to a hand-sewn anastomosis because of, for example,
nonsatisfactory blood flow, the surgeon dissolved the anastomosis
by pulling at the toe of the graft and thereby removing the staple
Figure 1. A, The Cardica C-Port System. B, Close-up view of the
C-Port cartridge and anvil. The anvil is 1 mm in diameter and has
incorporated an arteriotomy knife. The cartridge contains 8 clips.attachments in a zipper-like fashion. With this type of traction, in
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penetration through the target vessel wall similar in size to those
experienced after puncturing a target vessel wall with a 6-0 Pro-
lene needle (Ethicon, Inc, Somerville, NJ). The staple penetrates
the target vessel wall approximately 0.25 mm from the arteriotomy
edge. Should the staple tear through the target vessel wall, a
serrated target vessel wall edge is left behind that remains suitable
for a hand-sewn anastomosis.
Core Laboratory Analysis
The patency of the index grafts was evaluated by means of either
angiography or computed tomography (CT). The digital-film im-
ages were assessed by respective core laboratories. Assessment of
angiographies and CT scans were performed at Stanford Univer-
sity Medical Center under the direction of Edwin Alderman (an-
giography) and Geoffrey Rubin (CT). For angiographic images,
distal anastomosis patency was classified according to the FitzGib-
bon scoring system.3 C-Port anastomoses evaluated by means of
CT were classified as patent if there was positive contrastation in
the graft, including the distal anastomosis and target vessel. Be-
cause of the known limitations of CT, these data were excluded in
the patency statistics.
The Core Angiographic Laboratory at Stanford used both qual-
Figure 2. Main steps of loading the vein to the C-Port
on one side and inserted between the cartridge arms. T
the heel surface of the cartridge. The graft is then s
attached to the control spikes at the toe. The dista
anastomosis is completed.itative and quantitative methods to evaluate each anastomosis.
The Journal of ThoracicQualitative methods included estimates of thrombolysis in myo-
cardial infarction flow grade and general assessments of patency.
The quantitative coronary angiography laboratory included mea-
surement of the internal lumen dimensions of the graft proximal to
the distal anastomosis (A), the coronary target distal to the anas-
tomosis (C), and the internal diameter of the anastomosis itself (B).
This was performed by the core laboratory using standard angio-
graphic computer software (PlusPlus; Sanders Data Systems, Stan-
ford, Calif). These dimensions made it possible to calculate the
average percentage diameter stenosis, as described by Caskey and
associates4: A C ⁄ 2 B ⁄ A C ⁄ 2. If there was a narrowing
in the proximity of the anastomosis, such as the toe or heel of the
anastomosis, the narrowest diameter was used as B in this formula.
A mean negative anastomotic stenosis indicates that the anastomotic
diameter exceeds that of the surrounding graft or coronary artery.
Results
The details of patient enrollment and follow-up can be
derived from Figure 4. A total of 133 patients met preop-
erative and intraoperative inclusion and exclusion criteria.
The patient demographics are described in Table 1.
C-Port deployments were attempted in 130 patients and
ce at the toe (A) and the heel (B). The graft is incised
eel of the graft is then attached to 2 control spikes on
over the cartridge arms, and the toe of the graft is
stomosis can be done before or after the proximaldevi
he h
pread
l anawere successful in 119 patients. Eleven deployments were
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adequate tissue preparation of the target vessel or inappro-
priate target vessel selection, resulting in incomplete anas-
tomoses. In 3 additional patients intraoperative graft blood
was considered inadequate, and these C-Port anastomoses
were converted to hand-sewn anastomoses. Subsequent
blood flow measurements did not demonstrate an improve-
ment, suggesting poor target vessel run-off. Three patients
died before discharge of device-unrelated causes (right ven-
tricular failure–extracorporeal membrane oxygenation [n 
1], adult respiratory distress syndrome [n  1], and periop-
erative myocardial infarct after hemorrhage and resuscita-
tion [n  1]). In the patient with right ventricular failure,
autopsy was performed, and patency of the C-Port was
confirmed. Hemorrhage and myocardial infarction was re-
lated to a torn-off hand-sewn anastomosis. In this patient the
C-Port anastomosis was found to be patent. At discharge,
113 patients had a C-Port implant in place. In these patients
the C-Port device was placed as an end-to-side anastomosis
in 108 single grafts, 4 single sequential grafts, and 1 double
sequential graft. The diagonal coronary artery was grafted in
23%, circumflex branches were grafted in 62%, and the
distal segment of the right coronary artery was grafted in
15%. The average target vessel diameter was 1.6 0.4 mm.
Forty percent of all target vessels were less than or equal to
1.5 mm in internal diameter (core laboratory analysis).
Extracorporeal circulation and cardioplegia was established
in 96% of patients (n  109) during the construction of the
device anastomosis. An additional stitch at the toe and heel
Figure 3. Intimal view of a dissected human coronary artery after
in vitro deployment of the C-Port System. The C-Port System
creates a compliant end-to-side anastomosis.was necessary in almost all deployments. The average in-
1648 The Journal of Thoracic and Cardiovascular Surgery ● Dectraoperative blood flow was 41  25 mL/min. There were
no redo operations for bleeding or revision of the C-Port
anastomoses.
Discharge Patency
Of the 107 C-Port anastomoses studied by means of angiog-
raphy (n  104) and CT (n  3), 106 anastomoses were
found to be patent by the core laboratories, for a predis-
charge patency rate of 99% (106/107). In 3 patients the
C-Port distal anastomosis was rated FitzGibbon B. The
average distal anastomosis stenosis was 26.4%  31.8%.
The overall freedom of stenosis greater than 50% (FitzGib-
bon A) at discharge for grafts evaluated by means of an-
giography was therefore 96.2% (100/104).
Six-month Follow-up
Of the 113 patients discharged, one patient died 5 months
postoperatively of lung cancer, 6 patients voluntarily with-
drew, and 1 patient was unable to return because of illness.
Therefore at 6 months, 105 patients returned for clinical
follow-up (93.8% [105/112]); 98% were in Canadian Car-
diovascular Society class 0 or 1, and 99% were in NYHA
class I or II. None of the patients had a myocardial infarc-
tion or target vessel revascularization associated with an
index graft since discharge (MACE  0).
Of these patients, 98 (87.5% [98/112]) were evaluated by
means of angiography (n  89) or CT (n  9). The results
indicated that 85 C-Port index grafts evaluated by means of
angiography and all 9 C-Port index grafts evaluated by
means of CT were patent, for a rate of 95.9% (94/98). Three
C-Port index grafts evaluated by means of angiography
were rated FitzGibbon B, and 4 were rated FitzGibbon 0.
Excluding the 4 occluded anastomoses, the average distal
anastomosis stenosis was 10.7%  30.3%, with a mini-
mum of –116% and a maximum of 71%. The overall
freedom of stenosis greater than 50% (FitzGibbon A) in
grafts evaluated by means of angiography at 6 months was
therefore 92.1% (82/89). In the core laboratory analysis
there was no evidence of any narrowing of the coronary
artery at the site of the anvil insertion hole.
Twelve-month Follow-up
At 12 months postoperatively, 3 additional patients had died
of causes unrelated to the C-Port anastomosis (renal failure,
cerebral tumor, and recurrent strokes), and 107 implanted
patients returned, for a compliance rate of 98.2% (107/109).
Of these patients, 93% were in Canadian Cardiovascular
Society class 0 or I, and 98% were in NYHA class II or I.
None of the patients had a recent myocardial infarction or
target vessel revascularization associated with an index
graft (MACE  0). At the time of follow-up, 68% of the
patients were treated with aspirin only. In 91 implanted
patients a stress ECG was performed, and 93.4% (n  85)
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positive result in 6 patients. In one patient the C-Port graft
had been diagnosed to be occluded in the 6-month angio-
gram. In 3 patients additional angiograms were performed at
17 to 20 months postoperatively, which all showed the
C-Port graft to be patent. The cause of the ischemia in one
patient remained unclear, and in the remaining patient, the
same pattern of ischemia had been detected in a 3-month
stress ECG, and the index graft was found to be patent at 6
Figure 4. Patient flow chart. CT, Compumonths. The 11 patients with unsuccessful deployments and
The Journal of Thoracic3 patients in whom the C-Port anastomoses had been con-
verted to hand-sewn anastomoses because of poor blood
flow (Figure 4) were also followed at 12 months postoper-
atively. Of these 14 patients, 1 patient died 4 months post-
operatively because of recurrent strokes. The remaining 13
patients were well and without MACEs at 12 months.
Discussion
The potential advantages of using distal anastomotic de-
tomography; ECG, electrocardiography.tedvices are to rapidly and reliably produce a consistent con-
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should be done in a standardized fashion and requires min-
imal training. Anastomotic devices must be designed to
successfully cope with variations in patient anatomy and
vascular disease.5 Finally, yet importantly, easy removal in
the event of device malfunction should be possible. In this
study we were able to demonstrate that the C-Port System
favorably addresses the majority of these requirements.
Because of its novel design, the C-Port System is able to
administer all functions necessary to create a compliant
anastomosis in a single step. This makes rapid deployment
TABLE 1. Baseline demographics and clinical
characteristics
Condition
Enrolled patients
(n  133), n
Evaluable patients
per protocol
(n  113), n
Age (y), mean  SD 68.5  7.7 (133) 68.6  8.0 (113)
Confidence interval 67.2-69.8 67.1-70.1
Male sex 111 (83.5%) 94 (83.2%)
History of smoking 69 (51.9%) 57 (50.4%)
Family history of coronary
artery disease 49/111 (44.1%) 41/98 (41.8%)
Diabetes 48 (36.1%) 42 (37.2%)
Morbid obesity 6 (4.5%) 5 (4.4%)
Hyperlipidemia 105/131 (80.2%) 88/111 (79.3%)
Renal dysfunction 0 (0%) 0 (0%)
Chronic obstructive
pulmonary disease 18/129 (14.0%) 15/109 (13.8%)
Peripheral vascular
disease 19 (14.3%) 15 (13.3%)
Hypertension 108/132 (81.8%) 90/112 (80.4%)
Cerebrovascular accident 4 (3.0%) 0 (0%)
Infectious endocarditis 0 (0%) 0 (0%)
Hepatic failure 4 (3.0%) 3 (2.7%)
Prior myocardial
infarction 58 (43.6%) 49 (43.4%)
Angina 117 (88.0%) 99 (87.6%)
Arrhythmia 33 (24.8%) 26 (23.0%)
Congestive heart failure 0 (0%) 0 (0%)
Bleeding disorder 0 (0%) 0 (0%)
CCS class III or IV 66 (49.6%) 52 (46.1%)
NYHA class III* 51 (38.4%) 42 (37.2%)
No. of diseased vessels
Single 3 (2.3%) 3 (2.7%)
Double 40 (30.1%) 33 (29.2%)
Triple 90 (67.7%) 77 (68.1%)
Left main disease 19/132 (14.4%) 17/112 (15.2%)
Ejection fraction (%),
mean  SD 59.4  12.6 (133) 59.4  13.3 (113)
Confidence interval 57.2-61.5 57-61.9
SD, Standard deviation; CCS, Canadian Cardiovascular Society; NYHA,
New York Heart Association. *New York Heart Association class IV was a
preoperative exclusion criterion.possible. Its reliability, with 11 device malfunctions in 130
1650 The Journal of Thoracic and Cardiovascular Surgery ● Decattempts (8.5% failure rate), was satisfactory for a novel
product, especially because all failed deployments were not
technical but rather related to technique and vessel selec-
tion. Successful deployment with the C-Port System re-
quires alignment of the cartridge bays with the anvil that has
been placed inside the coronary artery. This can be achieved
by means of dissection of the upper 50% of the circumfer-
ence of the coronary artery or by avoiding intramural tar-
gets. If the cartridge cannot align with the anvil because of
tissue interference, the staples will not form on the anvil,
and the anastomosis will be incomplete. This was the cause
for the majority of the failures observed and allowed easy
conversion to a hand-sewn anastomosis. A second type of
failure was related to the limitations of the arteriotomy knife
to create an arteriotomy in target vessels with more than
0.75-mm wall thickness. In these instances the anastomosis
was removed, and the anvil insertion hole was extended to
create an adequate arteriotomy for hand-sewn anastomoses.
Because of the design of the product, the distance be-
tween clips is marginally larger at the toe and heel. In many
instances during this trial, additional conventional stitches
were placed to achieve hemostasis. However, this limitation
is offset by the ability to perform a consistent, reproducible,
and compliant anastomosis on target vessels as small as
1 mm in diameter. Future product iterations will address this
shortcoming.
In patients in whom the C-Port deployment was clini-
cally unsuccessful, a safe bailout with conversion to a
hand-sewn anastomosis was possible in all cases, without
any compromise to patient long-term outcome. At the end of
each procedure, the patient was informed of the success of
the deployment, and many patients in whom the deployment
was unsuccessful elected to refuse angiographic follow-up.
Any alternative technique used to construct a distal anas-
tomosis in coronary surgery should provide patency similar
to that obtained with conventional suturing techniques using
the same type of graft. Mack and associates presented a
meta-analysis at the Techno College, EACTS 2004 (Euro-
pean Association of Cardio-Thoracic Surgeons), comprising
more than 28,000 grafts. According to these researchers, the
patency of hand-sewn saphenous vein grafts can be ex-
pected to be 87.9% after 30 days, 84.1% between 3 and 6
months, 82.7% after 12 months, and 74.3% between 2 and
5 years. In this initial C-Port trial, graft patency (FitzGibbon
A and B) exceeded the meta-analysis benchmark, with
discharge patency of 99% and 6-month patency of 95.9%.
Further evaluation of the C-Port grafts with significant
stenosis or occlusion revealed that 5 of these 7 grafts were
anastomosed to coronary arteries with a native stenosis of
less than or equal to 60%. According to Manninen and
coworkers,6 reduced native artery stenosis is a predictor of
graft occlusion caused by competitive flow.
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of stress ECG and determination of MACEs, demonstrated
a favorable outcome in patients after implantation of the
C-Port System. None of the patients experienced a myocar-
dial infarction or required a target vessel revascularization
since discharge. The overall mortality since discharge
(3.6%) compares with published data by Cheng and col-
leagues7 and Unger and associates,8 who describe a 1-year
mortality of 2.6% and 3.6%, respectively. In addition, Un-
ger and associates found a myocardial infarction rate of
4.1% in more than 600 patients studied 1 year
postoperatively.
The C-Port anastomosis system has some important
characteristics that might help explain this favorable out-
come. The attachment of the graft to the target vessel is
accomplished with individual clips, which results in a com-
pliant anastomosis. The vascular anastomosis originally de-
veloped by Alexis Carrel used a modified interrupted tech-
nique. Cardiac surgeons adopted this technique, and some
of the pivotal studies describing long-term patency outcome
in CABG surgery by Loop and coworkers9 and Lytle and
colleagues10 are based on the interrupted technique. Wolf
and associates11 have recently published results from a
clinical trial in which multiple clips were used to perform an
interrupted anastomosis in the left internal thoracic artery–
to–left anterior descending coronary artery bypass grafts.
According to these authors, this technique avoided a steno-
Figure 5. Six-month angiogram of a saphenous vein–to– obtuse
marginal branch using the C-Port System.sis of the anastomosis, which can amount to 24% in the
The Journal of Thoracichand-sewn continuous stitch technique. In addition to pro-
viding a compliant anastomosis, the C-Port System clips
have a small amount of blood-exposed nonintimal surface
(Figure 3). Scheltes and coworkers12 studied various anas-
tomotic devices, compared them with sutured anastomoses,
and postulated that a reduction in blood-exposed nonintimal
surface would be beneficial for long-term outcome. The
automated creation of the anastomosis ensures consistency
from one anastomosis to another. Finally, the C-Port System
allows placement of the distal anastomosis without inter-
rupting native artery blood flow, thereby avoiding the need
for intracoronary shunts or temporary myocardial ischemia.
Limitations of the study include a nonrandomized patient
population selected for conformance with prespecified in-
clusion and exclusion criteria.
In summary, the 6-month patency rate and 12-month
clinical outcome of the C-Port device is very promising. On
the basis of these successful results, we have continued
evaluation of this product in successive studies with longer-
term follow-up. The integrated design of this product allows
rapid and safe deployment and might prove to be a valuable
asset in coronary surgery, especially in beating-heart pro-
cedures (off-pump coronary artery bypass).
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Discussion
Dr Pascal A. Berdat (Berne, Switzerland). Some years ago, the
development of devices to facilitate and accelerate vascular con-
nections in CABG surgery was thought to revolutionize the pro-
cedure and to induce a beneficial effect on the adoption of beating-
heart and even endoscopic bypass surgery. Demertzis and
colleagues present early angiographic and clinical results obtained
in distal coronary anastomosis by using the Cardica C-Port device.
This system has truly some advantages over other devices seen in
the past: the size of the target vessel can be as small as 1 to 1.5
mm; the sequence of performing the distal anastomosis first or last
is up to the surgeon; and most important, the anastomosis is
pulsatile and compliant.
With this study, the authors demonstrate good safety and effi-
cacy of this novel technology and have to be congratulated for
their excellent results. Efficacy in this context involves both suc-
cessful application of the device and creation of the patent anas-
tomosis. Because this is a feasibility trial with an intention-to-treat
model, the success rate of delivering the system was a fair 85%
because it was successfully applied in 116 of 133 patients initially
enrolled. In 11 patients conversion to a hand-sewn anastomosis
was necessary; in 3 patients poor blood flow across the graft also
made the redo of the anastomosis by hand necessary; 2 other
patients were deemed unsuitable for the use of the device; and
finally, in another patient the device failed because of a technical
problem.
What about efficacy in terms of creation of a patent anastomo-
sis? Although not all patients were followed up by means of
angiography or CT, patency rates were excellent, with a FitzGib-
bon A rating at discharge of 96% and 93% after 6 months. Given
the fact that all these grafts were veins and the target vessels were
mainly branches of the circumflex, the diagonal, or the right
coronary arteries, this is a very good result. However, more de-
tailed information on how these anastomoses looked should be
provided. I believe that classifying these anastomoses into FitzGib-
bon scores is not precise enough, and the anastomoses should be
better characterized. Can you comment on this?
1652 The Journal of Thoracic and Cardiovascular Surgery ● DecDr Demertzis. Yes. I would like to address the issue of efficacy
first. You mentioned the 11 unsuccessful deployments. The un-
successful deployments were due to the fact that the cartridge has
to align with the anvil and the tissue around the coronary artery has
to be dissected to a sufficient amount. If this is not the case, the
clips could miss the anvil and not deform, leading to a clinically
unsuccessful anastomosis. This is not a true failure. It is a tech-
nique failure and not a technical failure.
The other reason to have a clinically unsuccessful deployment
is if you do not respect the specs on the wall thickness of the target
vessel. Therefore in a target vessel that is heavily diseased and
thickened, you can have an unsuccessful deployment. This was the
case in the initial phase of the study. As we understood the reasons
for that and applied these criteria to our target vessels, this problem
dissolved. At the end of this study and later on during the C-Port’s
commercial use, this problem has actually disappeared.
With regard to the FitzGibbon classification, we do have a
complete quantitative graft and anastomosis analysis for every
graft in every single patient, very precise and exact. Of course,
with the FitzGibbon’s classification, he have a rough way to group
the grafts, and this is why it is widely used in the literature.
Therefore for the sake of comparison, I think it is a rather adequate
solution.
Dr Berdat. The use of this device seems rather safe, but there
are some technical particularities. The extensive preparation of the
vessel with dissection of 50% of the circumference and the need
for creation of a separate incision and insertion of this device is not
what could be called a no-touch technique. Furthermore, additional
stitches precisely at the most sensitive points of the anastomoses,
at the toe and heel, were usually necessary in this series. Can you
comment on this?
Dr Demertzis. It was not intended to have a coronary anasto-
mosis by not touching the coronary artery, of course.
The point on the stitches, yes, I have to mention that the tacking
stitches were really superficial adventitial stitches and not trans-
mural, which were absolutely sufficient in all the cases. You have
to deal with the anvil insertion hole, which is somewhere around
1 mm behind the heel of the anastomosis. Quantitative analysis on
the postoperative angiographs at discharge and at 6 months post-
operatively did not reveal any problem in respect to that issue.
Therefore it is a theoretic concern, but in real-world practice, it did
not have any effect.
Dr Berdat. Again, the authors have to be congratulated to put
their efforts in a field that has turned out to be controversial most
recently.
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